If we want to find a stock that could multiply over the long term, what are the underlying trends we should look for? Firstly, we'll want to see a proven return on capital employed (ROCE) that is increasing, and secondly, an expanding base of capital employed. Basically this means that a company has profitable initiatives that it can continue to reinvest in, which is a trait of a compounding machine. Having said that, from a first glance at Nipro (TSE:8086) we aren't jumping out of our chairs at how returns are trending, but let's have a deeper look.
What Is Return On Capital Employed (ROCE)?
Just to clarify if you're unsure, ROCE is a metric for evaluating how much pre-tax income (in percentage terms) a company earns on the capital invested in its business. The formula for this calculation on Nipro is:
Return on Capital Employed = Earnings Before Interest and Tax (EBIT) ÷ (Total Assets - Current Liabilities)
0.036 = JP¥28b ÷ (JP¥1.1t - JP¥347b) (Based on the trailing twelve months to June 2025).
Therefore, Nipro has an ROCE of 3.6%. Ultimately, that's a low return and it under-performs the Medical Equipment industry average of 13%.
See our latest analysis for Nipro
In the above chart we have measured Nipro's prior ROCE against its prior performance, but the future is arguably more important. If you'd like to see what analysts are forecasting going forward, you should check out our free analyst report for Nipro .
What Does the ROCE Trend For Nipro Tell Us?
When we looked at the ROCE trend at Nipro, we didn't gain much confidence. Around five years ago the returns on capital were 4.7%, but since then they've fallen to 3.6%. On the other hand, the company has been employing more capital without a corresponding improvement in sales in the last year, which could suggest these investments are longer term plays. It may take some time before the company starts to see any change in earnings from these investments.
The Bottom Line
Bringing it all together, while we're somewhat encouraged by Nipro's reinvestment in its own business, we're aware that returns are shrinking. And investors may be recognizing these trends since the stock has only returned a total of 39% to shareholders over the last five years. Therefore, if you're looking for a multi-bagger, we'd propose looking at other options.
One more thing: We've identified 4 warning signs with Nipro (at least 1 which is a bit unpleasant) , and understanding these would certainly be useful.
While Nipro may not currently earn the highest returns, we've compiled a list of companies that currently earn more than 25% return on equity. Check out this free list here.
The New Payments ETF Is Live on NASDAQ:
Money is moving to real-time rails, and a newly listed ETF now gives investors direct exposure. Fast settlement. Institutional custody. Simple access.
Explore how this launch could reshape portfolios
Sponsored ContentValuation is complex, but we're here to simplify it.
Discover if Nipro might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
About TSE:8086
Nipro
Engages in the medical devices, pharmaceuticals, and pharma packaging businesses.
Good value with proven track record.
Similar Companies
Market Insights
Weekly Picks
THE KINGDOM OF BROWN GOODS: WHY MGPI IS BEING CRUSHED BY INVENTORY & PRIMED FOR RESURRECTION

Why Vertical Aerospace (NYSE: EVTL) is Worth Possibly Over 13x its Current Price

The Quiet Giant That Became AI’s Power Grid
Recently Updated Narratives

MINISO's fair value is projected at 26.69 with an anticipated PE ratio shift of 20x

Fiverr International will transform the freelance industry with AI-powered growth
Jackson Financial Stock: When Insurance Math Meets a Shifting Claims Landscape
Popular Narratives

MicroVision will explode future revenue by 380.37% with a vision towards success

Crazy Undervalued 42 Baggers Silver Play (Active & Running Mine)


